Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Dow
Johnson and Johnson
Fuji
Citi
Moodys
UBS
Harvard Business School
Federal Trade Commission
Accenture

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,598,257

« Back to Dashboard

Which drugs does patent 7,598,257 protect, and when does it expire?

Patent 7,598,257 protects JAKAFI and is included in one NDA.

This patent has ninety-five patent family members in thirty-three countries.
Summary for Patent: 7,598,257
Title:Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s): Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Voorhees, NJ)
Assignee: Incyte Corporation (Wilmington, DE)
Application Number:11/637,545
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 7,598,257

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-001 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF POLYCYTHEMIA VERA ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-001 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-002 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF POLYCYTHEMIA VERA ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-002 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-003 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF POLYCYTHEMIA VERA ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-003 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-004 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF POLYCYTHEMIA VERA ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-004 Nov 16, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-005 Nov 16, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS ➤ Sign Up
Incyte Corp JAKAFI ruxolitinib phosphate TABLET;ORAL 202192-005 Nov 16, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y FOR THE TREATMENT OF POLYCYTHEMIA VERA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,598,257

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,415,362 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors ➤ Sign Up
8,933,086 Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors ➤ Sign Up
9,814,722 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors ➤ Sign Up
8,946,245 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors ➤ Sign Up
9,206,187 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase ➤ Sign Up
9,662,335 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors ➤ Sign Up
9,079,912 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors ➤ Sign Up
8,530,485 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors ➤ Sign Up
8,541,425 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,598,257

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 057995 ➤ Sign Up
Austria 525374 ➤ Sign Up
Australia 2006326548 ➤ Sign Up
Brazil PI0619817 ➤ Sign Up
Canada 2632466 ➤ Sign Up
China 101448826 ➤ Sign Up
China 103214483 ➤ Sign Up
China 103214484 ➤ Sign Up
China 103254190 ➤ Sign Up
Costa Rica 10065 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Harvard Business School
US Army
Deloitte
Argus Health
Citi
Farmers Insurance
QuintilesIMS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot